Trial Profile
A retrospective study of extended rivaroxaban treatment for prevention of deep vein thrombosis and pulmonary embolism.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Sep 2017
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- 06 Dec 2016 Results of 3-month and 6-month treatment analysis, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 21 Nov 2016 New trial record